Psychedelics Are a Viable Solution to Mental
We’re at the threshold of industry transformation, as the stigmas and regulations shaping both psychedelics and mental health are challenged for the better.
The pathway for the psychedelics industry is optimistic, primed by the success of the cannabis space and international news of decriminalization. Since the first steps taken by Oregon to decriminalize psilocybin and legalize psychedelic-assisted therapy, stocks have skyrocketed for psychedelic therapy organizations in North America and the UK.
Why Analysts Think the Mental Health Industry Is Ripe for Growth
MINDCURE’s research, technology, and psychedelic compounds can disrupt mental health care by offering new alternatives where solutions are desperately needed, particularly in regard to confronting addiction.
12,472 treatment facilities as of 2019
As of 2019, there were 12,472 registered mental health treatment facilities in the U.S., which could benefit from an interconnected digital therapeutics platform, such as iSTRYM4
U.S. $7 billion by 2025
Where the addiction treatment market is expected to hit U.S. $7 billion by 2025, MINDCURE is joining the estimated $42 billion market for ibogaine-assisted treatment5
Recent section 56 exemptions
Regulatory bodies are quickly adapting to the demand for patient access for psychedelic medicines. Recent exemptions are opening doors to psilocybin treatment and clinical trials for approved terminally-ill patients
MINDCURE Company Highlights
MINDCURE is a diversified psychedelic research and technology company at the forefront of the mental health industry. With research into indications for psychedelic substances, digital therapeutics technology, and integrative partnerships, MINDCURE is prepared to offer what others in the space cannot.
A growing team of scientific experts in experimental medicine, integrative psychiatry, trauma, and regenerative medicine
Exciting partnerships amplifying our software platform & facilitating clinical research
Pricing delayed by 20 minutes.